Shandong Xinhua Pharmaceutical Company Limited Class H (HK:0719) has released an update. Shandong Xinhua Pharmaceutical ...

Akebia Therapeutics®, Inc. , a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the American Journal of Kidney Disease has ...

UNI-494 is targeting acute kidney injury (AKI), a challenging and often under-treated disease ... In the survey, OLC ...

The hope is that by using TPPs, more new tests will make it to patients and improve diagnosis and cancer care. The project aims to develop a TPP for new bladder and kidney cancer tests to help ...

The FDA has started a review of Unicycive Therapeutics' drug for hyperphosphataemia in patients with chronic kidney disease ...

More than 50 pieces, including sketches, paintings and collages, make up the exhibition as part of the Art in Hospital project at New Victoria Hospital in Glasgow’s southside. The project is ...

on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. Eighty percent of patients with CKD on ...

leading to phosphorus buildup in people with chronic kidney disease. High phosphorus levels pull calcium out of the bones, weakening bone structure. Elevated phosphorus levels can also result in ...

An interdisciplinary study involving eight University of Cincinnati College of Medicine experts has found significant sex differences in cardiovascular outcomes in patients with kidney failure.

AWAK Technologies’ wearable peritoneal dialysis (PD) device could allow kidney patients to perform dialysis on the go The device weighs 3 kg and eliminates the need for large dialysis machines ...

To evaluate the efficacy of calcium carbonate as an alternative phosphate binder, we studied 20 patients maintained on dialysis during three consecutive periods. In period 1, the patients took ...